AZN

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 36.59% Potential Upside and Strong Buy Ratings

AstraZeneca PLC (NASDAQ: AZN), a global leader in the biopharmaceutical sector, remains a focal point for investors due to its substantial market capitalization and promising growth prospects. With a market..

AstraZeneca reports positive Phase III results for Tagrisso-Orpathys lung cancer combination

Astrazeneca Plc has reported positive SAFFRON Phase III results for Tagrisso and Orpathys, showing improved progression-free and overall survival...

AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 32% Potential Upside Amid Strong Buy Ratings

AstraZeneca PLC (AZN), a leading biopharmaceutical titan based in Cambridge, UK, is making waves in the healthcare sector with its robust pipeline of prescription medicines. With a market capitalization of..

AstraZeneca PLC (AZN)

⚠️ No article content returned.

..

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 26% Potential Upside and Strong Buy Ratings

AstraZeneca PLC (NYSE: AZN), a stalwart in the healthcare sector, is commanding investor attention with its robust growth prospects and strategic positioning in the global pharmaceutical landscape. With a market..

AstraZeneca H1 2026 revenue rises 9% as growth momentum continues

AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in oncology and rare disease..

Astrazeneca reports positive survival data for Sone-Ve in gastric cancer trial

Astrazeneca Plc has reported statistically significant overall survival results for Sone-Ve in the CLARITY-Gastric01 Phase III trial...

Astrazeneca secures EU approval for Etcamah in ER-positive breast cancer

Astrazeneca Plc has secured European Union approval for Etcamah in combination therapy for ER-positive, HER2-negative advanced breast cancer...

AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 26.64% Potential Upside

AstraZeneca PLC (AZN), a stalwart in the healthcare sector, has long garnered attention for its innovation and robust product pipeline. As a leading entity in the general drug manufacturing industry,..

Astrazeneca secures global rights to Zegfrovy in EGFR-mutated lung cancer

Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio...

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 28.83% Potential Upside in the Healthcare Sector

AstraZeneca PLC (AZN), a prominent player in the healthcare sector, is capturing investor attention with a tantalizing potential upside of 28.83%. With its robust market capitalization of $266.15 billion, AstraZeneca..

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy.....

AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 14.93% Potential Upside for Investors

AstraZeneca PLC (AZN), a stalwart in the healthcare sector, continues to capture investor interest with its robust financial performance and strategic initiatives in the biopharmaceutical domain. As of the latest..

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 19% Upside and Robust Revenue Growth

AstraZeneca PLC (AZN), a titan in the healthcare sector, continues to draw attention from investors with its impressive market cap of $292.2 billion and a promising potential upside of 19.15%...

AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC

Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer...

AstraZeneca PLC (AZN) Stock Analysis: Robust Growth and Analyst Confidence Propel a 28% Upside Potential

AstraZeneca PLC (NASDAQ: AZN), a stalwart in the healthcare sector, is drawing significant investor interest with its impressive market cap of $271.29 billion and a promising potential upside of 28.33%...

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 25.59% Potential Upside with Strong Buy Ratings

AstraZeneca PLC (AZN), a titan in the healthcare sector, has garnered significant attention from investors, offering a potential upside of 25.59% as per recent analyst evaluations. With a market capitalization..

Astrazeneca Plc gains US approval for Truqap in PTEN-deficient prostate cancer

Astrazeneca Plc has gained US approval for Truqap with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer...

AstraZeneca PLC (AZN) Stock Analysis: Robust Revenue Growth and a 20.73% Upside Potential

AstraZeneca PLC (AZN) presents a compelling case for investors seeking opportunities within the healthcare sector. With its headquarters in Cambridge, United Kingdom, this biopharmaceutical titan boasts a market capitalization of..

AstraZeneca PLC (AZN) Stock Analysis: Evaluating a Promising 20.91% Upside Potential

AstraZeneca PLC (AZN), a titan in the healthcare sector, holds a prominent position in the drug manufacturing industry. With a staggering market capitalization of $287.95 billion, this UK-based biopharmaceutical powerhouse..

Search

Funds

AZN

AstraZeneca reports positive Phase III results for Tagrisso-Orpathys lung cancer combination

Astrazeneca Plc has reported positive SAFFRON Phase III results for Tagrisso and Orpathys, showing improved progression-free and overall survival...

AstraZeneca H1 2026 revenue rises 9% as growth momentum continues

AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in oncology and rare disease offset Farxiga and China headwinds. The company raised its interim dividend, secured 30 approvals, and reaffirmed full-year guidance and its $80 billion 2030 revenue goal...

Astrazeneca reports positive survival data for Sone-Ve in gastric cancer trial

Astrazeneca Plc has reported statistically significant overall survival results for Sone-Ve in the CLARITY-Gastric01 Phase III trial...

Astrazeneca secures EU approval for Etcamah in ER-positive breast cancer

Astrazeneca Plc has secured European Union approval for Etcamah in combination therapy for ER-positive, HER2-negative advanced breast cancer...

Astrazeneca secures global rights to Zegfrovy in EGFR-mutated lung cancer

Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio...

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy.....

AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC

Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer...

Astrazeneca Plc gains US approval for Truqap in PTEN-deficient prostate cancer

Astrazeneca Plc has gained US approval for Truqap with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer...
Search

Funds

AZN

FTSE 100

Funds